Omicron | Jotup

BNTX Class Action Reminder: Kessler Topaz Meltzer & Check, LLP Reminds BioNTech SE (BNTX) Investors of Securities Fraud Class Action Lawsuit

Retrieved on:

Thursday, February 22, 2024

RADNOR, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against BioNTech SE (“BioNTech”) ( NASDAQ: BNTX ).

Key Points:

RADNOR, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against BioNTech SE (“BioNTech”) ( NASDAQ: BNTX ).
The action charges BioNTech with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
As a result of BioNTech’ s materially misleading statements and omissions to the public, BioNTech’ s investors have suffered significant losses.
Kessler Topaz Meltzer & Check, LLP encourages BioNTech investors who have suffered significant losses to contact the firm directly to acquire more information.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTech SE of Class Action Lawsuit and Upcoming Deadlines – BNTX

Retrieved on:

Tuesday, February 20, 2024

NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX).

Key Points:

NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX).
Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
BioNTech is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases.
Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

BNTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that BioNTech SE Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on:

Monday, February 19, 2024

Pfizer–BioNTech COVID-19 vaccine, Pfizer, Cancer, Court, Biotechnology, Person, The Company, BioNTech, Omicron, Food, Complaint, Risk, COVID-19, BNTX, Infection, Pharmaceutical industry

BioNTech is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases.

Key Points:

BioNTech is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases.
The Company has developed and continues to develop, among other products and product candidates, Comirnaty, a COVID-19 vaccine, in collaboration with Pfizer Inc. (“Pfizer”).
or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress

Retrieved on:

Thursday, March 7, 2024

“I am excited about the continued pipeline progress and efforts toward commercialization achieved by Arcturus in 2023,” said Joseph Payne, President & CEO of Arcturus Therapeutics.

Key Points:

“I am excited about the continued pipeline progress and efforts toward commercialization achieved by Arcturus in 2023,” said Joseph Payne, President & CEO of Arcturus Therapeutics.
This marks the first marketing approval milestone for CSL and Arcturus since signing the Collaboration and License agreement in November 2022.
In November 2023, Arcturus received Orphan Drug Designation from the U.S. FDA for ARCT-032, for the treatment of Cystic Fibrosis.
We have achieved a total of approximately $396.0 million in upfront payments and milestones from CSL as of December 31, 2023.

New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19

Retrieved on:

Tuesday, March 5, 2024

Health, Infectious Diseases, Hospitals, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, Omicron, PCC, Dexamethasone, Senior, Patient, Mortality, Immunodeficiency, Gilead Sciences, CROI, MD, Risk, Pharmaceutical industry

One study showed Veklury® (remdesivir) was associated with a reduced risk of certain long-COVID symptoms in people who were hospitalized for COVID-19.

Key Points:

One study showed Veklury® (remdesivir) was associated with a reduced risk of certain long-COVID symptoms in people who were hospitalized for COVID-19.
“As we enter the fourth year of COVID-19, Veklury remains the antiviral standard of care for people hospitalized for COVID-19.
Results from this analysis build on existing evidence that support the importance of treating COVID-19 early in the disease course with an antiviral.
Patients on invasive mechanical ventilation/ECMO at baseline had a 19% (p=0.0182) reduced risk for mortality at Day 28.

Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Against BioNTech SE (BNTX) and Urges BNTX Investors with Substantial Losses to Contact the Firm

Retrieved on:

Monday, March 4, 2024

The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed against BioNTech SE (“BioNTech”) ( NASDAQ: BNTX ).

Key Points:

The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed against BioNTech SE (“BioNTech”) ( NASDAQ: BNTX ).
The action charges BioNTech with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
As a result of BioNTech’ s materially misleading statements and omissions to the public, BioNTech’ s investors have suffered significant losses.
Kessler Topaz Meltzer & Check, LLP encourages BioNTech investors who have suffered significant losses to contact the firm directly to acquire more information.

Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024

Retrieved on:

Monday, February 26, 2024

Outcomes from pipeline research studies will also provide insights into investigational treatment candidates, including the novel combination regimen of lenacapavir plus bictegravir.

Key Points:

Outcomes from pipeline research studies will also provide insights into investigational treatment candidates, including the novel combination regimen of lenacapavir plus bictegravir.
Additionally, a late-breaker oral presentation of Week 24 data from the INSIGHT trial evaluating Biktarvy in people with HIV and tuberculosis will be presented.
Gilead will present new data evaluating the safety and efficacy of Hepcludex® (bulevirtide) in people living with the coinfections of HIV, hepatitis B (HBV) and hepatitis delta (HDV).
Biktarvy combines the novel, unboosted INSTI bictegravir, with the Descovy® (emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, F/TAF) backbone.

Medical Waste Management Market Worth $12.2 billion | MarketsandMarkets™

Retrieved on:

Friday, March 8, 2024

Key Market Players of Medical Waste Management Industry:

Key Points:

Key Market Players of Medical Waste Management Industry:
The major players operating in this market are Veolia Environnement S.A. (France), Clean Harbors, Inc. (US), Stericycle Inc. (US), Waste Management, Inc. (US), Cleanaway Waste Management Limited (Australia), Casella Waste Systems, Inc. (US), Sharps Compliance, Inc. (US), Covanta Holding Corporation (US), Hazardous Waste Experts (US), REMONDIS SE & Co. KG.
(UK), BioMedical Waste Solutions, LLC (US), EcoMed Services (Canada), GRP & Associates, Inc. (US), BWS Incorporated (US), MEDPRO Disposal LLC (US), GIC Medical Disposal (Canada), Gamma Waste Services (US), Triumvirate Environmental (US), EPCO (Saudi Arabia), All Medical Waste Australia Pty Ltd. (Australia), Pro-Disposal Medical Waste Services (Georgia), SSO Medical Waste Management (US), Safeguard Waste Solutions (US), MedWaste Industries Inc. (US), DULSCO (UAE).
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=1256
Medical Waste Management Market - Key Benefits of Buying the Report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall medical waste management market and the subsegments.
Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the medical waste management market
Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Veolia Environnement S.A. (France), Clean Harbors, Inc. (US), Stericycle Inc. (US), Waste Management, Inc. (US), Cleanaway Waste Management Limited (Australia), Casella Waste Systems, Inc. (US), Sharps Compliance, Inc. (US), among others in the medical waste management market strategies.

New CDC Respiratory Guidance Ignores Kidney Patient Concerns

Retrieved on:

Thursday, March 7, 2024

WASHINGTON, March 7, 2024 /PRNewswire/ -- Today, the American Association of Kidney Patients (AAKP), the largest and oldest independent kidney patient organization in the nation, issued an Official Statement (appears below) in response to the Center for Disease Prevention and Control's (CDC) new Respiratory Virus Guidance, publicly announced on March 1, 2024. The CDC announcement occurred on the first day of National Kidney Month. March traditionally unites kidney stakeholders and people of goodwill in efforts to raise awareness of kidney diseases, address ongoing unmet patient needs, and advocate for removal of federal regulatory and payment barriers that impede access to, and development of, new kidney diagnostics, drugs, and devices.

Key Points:

Mortality rates among kidney patients occurred at historic levels at the start of the COVID pandemic, devastated the kidney patient community and families, and this community's ongoing risks remain a strategic concern among patient advocates and allied kidney professionals.
AAKP also raised kidney patient health and safety concerns to CDC officials in stakeholder briefings prior to the March 1, 2024, CDC Respiratory Virus Guidance announcement.
The American Association of Kidney Patients (AAKP), the nation's largest and oldest independent kidney patient organization in the nation, is deeply concerned about the Center for Disease Prevention Control's (CDC) Respiratory Virus Guidelines, including for COVID, announced on March 1, 2024.
https://www.cdc.gov/mmwr/volumes/73/wr/mm7308a5.htm
Since 1969, The American Association of Kidney Patients has been a patient-led organization driving policy discussions on kidney patient care choice and medical innovation.

BIONTECH INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioNTech To Contact Him Directly To Discuss Their Options

Retrieved on:

Thursday, February 15, 2024

NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX) and reminds investors of the March 12, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points:

Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
The Company attributed the result, in part, to the "dynamic" development of the pandemic, which "caus[ed] a re-phasing of orders and .
Faruqi & Faruqi, LLP also encourages anyone with information regarding BioNTech’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).